Today’s blog is about oripavine, the next product in Antheia’s pipeline following the successful commercial launch of thebaine. Read on for more about how oripavine is used in modern medicine, why this ingredient is vulnerable to supply chain disruptions, and what a modern approach to manufacturing it means for the future of public health.
Most people have never heard of oripavine, but it plays a critical role in public health. The compound is a key starting material (KSM) for several essential medicines used in overdose rescue, addiction treatment, and pain management. These include naloxone, buprenorphine, naltrexone, and hydromorphone, among others.
Despite its importance, traditional oripavine production faces significant limitations that contribute to harmful drug shortages both in the United States and globally. To better understand the issue, we’ll explore how oripavine-based medicines are used and produced today, and how biomanufacturing can help overcome these challenges to improve access for the people who need it most.
Oripavine in addiction treatment
Oripavine-based medicines have become a lifeline for many people struggling with addiction.
Naloxone, an overdose rescue medication best known as the nasal spray Narcan, is probably the most familiar of these medicines. While naloxone is used for emergencies, buprenorphine and naltrexone are critical parts of ongoing addiction treatment plans. Buprenorphine is a partial opioid agonist, meaning it binds to some opioid receptors in the brain while blocking others. It can reduce drug cravings and withdrawal symptoms, giving patients relief from some of the hardest parts of recovery. Because buprenorphine is an opioid, it is often formulated with naloxone to prevent misuse. Buprenorphine is also one of just two recommended treatments for pregnant women with opioid use disorder, making it an important tool for the most vulnerable patients. Naltrexone is a full opioid antagonist that completely blocks the euphoric effects of opioids, reducing the risk of overdose and preventing potential misuse. Naltrexone is also widely used for alcohol use disorder by binding to endorphin receptors and blocking the effects of alcohol. Naltrexone dulls cravings and pleasure associated with drinking, helping patients to maintain sobriety.
In the last several years, policy changes have made addiction treatments more readily available, including the 2023 approval of over-the-counter Narcan. Officials at the federal, state, and local levels all kicked off awareness campaigns to educate the broader public on Narcan, with many localities offering free training and bystander kits to anyone hoping to help. That same year, Congress eliminated several restrictions on buprenorphine. The change empowered any DEA-authorized clinician to prescribe it, significantly increasing access.
Those changes — alongside community-based harm reduction interventions and federal and state efforts to cut off the supply of illicit drugs — have contributed to a sharp drop in overdose deaths, with a 40 percent reduction since 2023.
Access to Narcan, buprenorphine, and other addiction medications like naltrexone have made a measurable difference, and we must continue to build on this momentum. It is critical that our supply chains are equipped to both meet existing demand and expand the reach of these life-saving medicines. But with continued reliance on legacy manufacturing approaches, our global pharmaceutical supplies will remain unpredictable at best. Next, we’ll look at another oripavine-based medicine: hydromorphone.
Oripavine in pain management
Hydromorphone is an oripavine-based opioid used by patients with severe, long-lasting pain. It is commonly used in intensive care units to help intubated patients tolerate ventilators, and was in high demand, and eventually in urgent shortage, during the COVID-19 pandemic. It is on the FDA and ASPR 86 Essential Medicine lists and is currently in shortage, reflecting the fragility of our pharmaceutical supply chains. The causes of this most recent shortage include shipping delays, manufacturing issues, and an inability to respond to changes in demand.
Each of those causes reflects a severe disruption in the years-long journey of drug production. That journey starts with the poppy plant. Because the starting materials for these drugs come from poppy crops, they are highly vulnerable to issues that plague traditional agriculture-based production. Decisions about how much to plant and harvest are made years in advance, making it impossible for producers to quickly respond to demand spikes. More frequent natural disasters, pests, and unpredictable crop yields can also affect KSM availability, which ripples through the rest of the production process. On the manufacturing side, quality issues, regulatory actions, and production failures contribute to delays, further slowing the long process. Once a drug is finished and ready to ship, geopolitical tensions can derail this leg of the journey, as we’ve seen with the Strait of Hormuz this year. These compounding production challenges and supply chain disruptions all lead to the same result: patients struggling to access the medicines they need.
Why oripavine supply is less predictable
Many oripavine-based medicines can also be made with thebaine, another poppy-derived KSM, but oripavine has become increasingly preferred because it requires fewer steps in the synthesis process. The tradeoff is supply. Poppy varieties are bred to produce specific KSMs, and the varieties that yield oripavine are harder to grow than those that yield thebaine. As a result, oripavine is produced at a smaller scale, and in some years, supply falls short of what manufacturers need.
Switching starting materials isn’t a simple fix. Changing a drug’s manufacturing process is time- and resource-intensive, especially when it comes to regulatory approvals. Without a clear return on investment, manufacturers are reluctant to switch, which makes it hard to respond when a preferred starting material becomes scarce. For those relying on an oripavine-based process, there are few options when supply tightens.
How biomanufacturing can help
Antheia’s advanced biosynthesis platform unlocks new possibilities for its pharmaceutical customers. Unlike agriculture-based supply chains, Antheia’s fermentation-based process delivers high-quality pharmaceutical ingredients in weeks rather than years, with predictable costs and a more reliable supply.
Oripavine is a close derivative of thebaine, so Antheia was able to leverage the strain, fermentation, and downstream process work already completed for its first product. This has enabled a faster path to commercialization, with Antheia’s biosynthetic oripavine launching soon. This technological breakthrough combined with Antheia’s proven approach to commercial-scale biomanufacturing stands to fundamentally transform the supply chains for oripavine-based medicines, and other critical pharmaceutical ingredients.
With both thebaine and oripavine in Antheia’s pipeline, drugmakers can continue using the starting material that best fits their chemistry. For new entrants and companies updating their processes, this means having the option to select the technically preferred KSM. In either case, Antheia’s customers’ supply chains are backed by a reliable, resilient supplier.
By reimagining how these critical pharmaceutical ingredients are made, we can stabilize supply, respond rapidly to demand shifts, and improve public health outcomes.
Follow Antheia on LinkedIn.